| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.9K | 1.8% | 10.8% |
| Total Income | 1.9K | 1.3% | 11.1% |
| Expenditure | 1.7K | 0.5% | 10.6% |
| PBT | 163.34 | 26.5% | 7.9% |
| Net Profit | 131.95 | 28.2% | 4.2% |
| OPM | 13.39% | 3.14pp | 8.92pp |
| NPM | 6.97% | 2.61pp | 1.10pp |
| EPS | 6.76 | 28.1% | 3.6% |
Alembic Pharmaceuticals Reports 11% Revenue Growth in Q3 FY26
05 Feb 2026 · 5 Feb, 2:26 pm
Summary
Alembic Pharmaceuticals Limited reported its consolidated financial results for the third quarter and nine months ended 31st December 2025. The company's revenue from operations increased by 11% to Rs.1,876 Cr. EBITDA increased by 14% to Rs. 308 Cr, and Profit Before Exceptional Items and Tax increased by 15% to Rs 205 Cr. The company reported a Profit After Tax of Rs.133 Cr after a one-time provision of Rs 42 Cr towards employee benefits.
Key Highlights
- 1
Revenue from operations increased by 11% to Rs.1,876 Cr.
- 2
EBITDA increased by 14% to Rs. 308 Cr.
- 3
Profit Before Exceptional Items and Tax increased by 15% to Rs 205 Cr.
- 4
India Branded Business delivered a 6% YoY growth, reaching Rs 652 Cr. in revenue for the quarter.
- 5
US Generics grew by 6% to Rs. 553 Cr. for the quarter.
- 6
Ex-US International Generics grew by 36% to Rs. 406 Cr. for the quarter.
- 7
API business grew by 2% to Rs. 264 Cr. for the quarter.
Management Comments
Mr. Pranav Amin
Our Q3 performance underscores the sustained momentum across our businesses supported by consistent execution, continued focus on profitability and operating rhythm. We further strengthened our presence in Australia, Canada, Europe, the USA and other key markets delivering an overall growth of 11%. Our pre-R&D EBITDA margin at 25% remains healthy. We continued to invest around 9% of revenue in R&D to build a robust pipeline for future growth. The integration of Utility Therapeutics progressed well, and we are working towards launch of Pivya™ in quarter 4 positioning us to expand our footprint in branded drugs in the US and create new avenues for sustainable growth.
Informational and educational content only. Not investment advice.